SCHEMBL13337366

SCHEMBL13337366

CCOC(=O)CN/N=N/c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
NPC1 O15118 2/20 0.49
MAPT P10636 10/20 0.48
ALDH1A1 P00352 5/20 0.48
MAPK1 P28482 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
LMNA P02545 6/20 0.46
KDM4E B2RXH2 3/20 0.45
BCL9 O00512 1/20 0.45
CTNNB1 P35222 1/20 0.45
GAA P10253 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
AR P10275 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3426161 0.80 MAPT (0.55) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL28802712 0.77 MAPT (0.48) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL7716236 0.76 PTGS2 (0.57) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL7716238 0.76 PTGS2 (0.57) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL8725883 0.76 PTGS2 (0.57) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL17182750 0.76 MAPT (0.59) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL17182751 0.76 MAPT (0.59) RAB9AKMT2AMEN1NPC1MAPT
Ethane SCHEMBL7845714 0.75 MAPT (0.57) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL4049519 0.74 LMNA (0.55) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL1646935 0.74 MAPT (0.67) RAB9AKMT2AMEN1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871916-B2 Diaryl phosphine compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-10-28 US disclosed
US-20130203974-A1 Preparation of Diazo and Diazonium Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-08 US disclosed
US-8350014-B2 Preparation of diazo and diazonium compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-8350014-B2 Preparation of diazo and diazonium compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-20100125132-A1 PREPARATION OF DIAZO AND DIAZONIUM COMPOUNDS WISCONSIN ALUMNI RESEARCH FOUNDATION 2010-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125132-A1 PREPARATION OF DIAZO AND DIAZONIUM COMPOUNDS TREH, TALDO1, LIPE RAB9A 890/4885KMT2A 1865/4885MEN1 345/4885
US-20130203974-A1 Preparation of Diazo and Diazonium Compounds TREH, TALDO1, LIPE RAB9A 890/4885KMT2A 1865/4885MEN1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.